1228280-29-2

1228280-29-2 structure

Name: KY-05009
Chemical Name: 2-Anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide
CAS Number: 1228280-29-2
Molecular Formula: C₁₈H₁₆N₄O₂S
Molecular Weight: 352.410
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-06-04 17:14:35
Modify Date: 2025-08-26 19:39:52
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity[1].

Name	2-Anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide
Synonyms	MFCD29059915 4-Thiazolecarboxamide, 5-[(4-methylbenzoyl)amino]-2-(phenylamino)- 2-Anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide KY-05009

Description	KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity[1].
Related Catalog	Signaling Pathways >> MAPK/ERK Pathway >> MAP4K Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Stem Cell/Wnt >> Wnt
Target	TNIK:100 nM (Ki)
In Vitro	KY-05009 (0.1-30 μM; 24 hours; RPMI8226 cells) treatment inhibits the proliferation of RPMI8226 cells in a dose-dependent manner[1]. KY-05009 (1-3 μM; 48-72 hours; RPMI8226 cells) treatment induces caspase-dependent apoptosis in RPMI8226 cells in a dose-dependent manner[1]. KY-05009 (3 μM; 1 hour; RPMI8226 cells) treatment suppresses the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4[1]. .KY-05009 (3 μM; 9 hours; RPMI8226 cells) treatment inhibits the IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4[1]. Cell Proliferation Assay[1] Cell Line: RPMI8226 cells Concentration: 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM Incubation Time: 24 hours Result: Inhibited the proliferation of RPMI8226 cells. Apoptosis Analysis[1] Cell Line: RPMI8226 cells Concentration: 1 μM, 3 μM, 10 μM Incubation Time: 48 hours, 72 hours Result: Induced the binding of fluorescent Annexin V and 7-amino-actinomycin D (7-AAD) uptake. RT-PCR[1] Cell Line: RPMI8226 cells Concentration: 3 μM Incubation Time: 1 hour Result: Suppressed the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4. Western Blot Analysis[1] Cell Line: RPMI8226 cells Concentration: 3 μM Incubation Time: 9 hours Result: The IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4 were inhibited.
References	[1]. Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8(25):41091-41101.

Density	1.4±0.1 g/cm3
Molecular Formula	C₁₈H₁₆N₄O₂S
Molecular Weight	352.410
Exact Mass	352.099396
LogP	2.83
Index of Refraction	1.728

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Precautionary Statements	P301 + P312 + P330
RIDADR	NONH for all modes of transport

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1228280-29-2	1621673-53-7
2093406-88-1	2093407-25-9
1223284-75-0	2489390-15-8
468056-29-3	110816-78-9
92602-21-6	172544-75-1
1804685-37-7	1956371-79-1
1956331-66-0	1805408-87-0
1261868-24-9	1805170-66-4
1806804-64-7	1805131-70-7
1805415-66-0	1261635-64-6